When was Neogen TC founded?

Neogen TC was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Neogen TC located?

Neogen TC is headquartered in Seoul, South Korea.

Is Neogen TC a funded company?

Neogen TC is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Apr 06, 2021.

When was the latest funding round of Neogen TC?

Neogen TC's latest funding was a $***** Series A round on Apr 06, 2021, with participation from 8 investors.

Where does Neogen TC rank among its competitors?

Neogen TC ranks 1322nd amongst 3358 active competitors, of which 1145 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Neogen TC?

Neogen TC's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Neogen TC - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of cell therapies for the treatment of cancer. The company focuses on developing immune T-cell therapy based on a new antigen discovery platform. The company has developed a pipeline for breast and lung cancer.

Website: neogentc.com
Email ID: *****@neogentc.com
Phone Number: +82 **********

Key Metrics

Founded Year

2020

Location

Seoul, South Korea

Stage

Series A

Total Funding

$13.3M in 1 round

Latest Funding Round

Series A, Apr 06, 2021, $*****

Investors

Arche Investment & 9 more

Ranked

1322^nd among 3358 active competitors

Similar Companies

BeiGene & 806 more

View Neogen TC's full profile

Neogen TC is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Neogentc Co., Ltd. CIN: 888-86-01612 , South Korea, Active	Feb 10, 2020	-	-	-

Neogen TC has raised a total funding of $13.3M over 1 round. Its latest funding round was a Series A round on Apr 06, 2021 for $*****. 8 investors participated in its latest round. Neogen TC has 10 institutional investors.

Here is the list of recent funding rounds of Neogen TC:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 06, 2021	8202521	Series A	9500526	2405315	9657195	5622509

Access funding benchmarks and valuations. Sign up today!

View details of Neogen TC's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neogen TC include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Neogen TC, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1322nd	Neogen TC 2020, Seoul (South Korea), Series A	Developer of cell therapies for the treatment of cancer	$13.3M	Arche Investment, T S Investment & 8 others	36/100